摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-吡咯烷酮盐酸盐 | 3760-52-9

中文名称
3-吡咯烷酮盐酸盐
中文别名
——
英文名称
pyrrolidin-3-one hydrochloride
英文别名
3-pyrrolidone hydrochloride;pyrrolidin-3-one;hydrochloride
3-吡咯烷酮盐酸盐化学式
CAS
3760-52-9
化学式
C4H7NO*ClH
mdl
——
分子量
121.567
InChiKey
DPSTYIOIVSHZRI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    86-88°C dec.
  • 溶解度:
    可溶于二甲基亚砜、水

计算性质

  • 辛醇/水分配系数(LogP):
    -0.03
  • 重原子数:
    7
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    29.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:99aa7812fc5cac3cc321471710cfc85e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Pyrrolidin-3-one, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Pyrrolidin-3-one, HCl
CAS number: 3760-52-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H8ClNO
Molecular weight: 121.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3-吡咯烷酮盐酸盐(3-pyrrolidone hydrochloride,1)是一种重要的中间体,用于合成天然抗肿瘤药喜树碱(camptothecin)。

反应信息

  • 作为反应物:
    描述:
    AG221中间体C3-吡咯烷酮盐酸盐N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 以0.82 g的产率得到1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)pyrrolidin-3-one
    参考文献:
    名称:
    三嗪类化合物、其制备方法及用途
    摘要:
    本发明属于医药化学领域,具体涉及三嗪类化合物、其制备方法及其作为参比对照品用于(S)‑3‑(三氟甲基)‑1‑(4‑(6‑(三氟甲基)吡啶‑2‑基)‑6‑(2‑(三氟甲基)吡啶‑4‑氨基)‑1,3,5‑三嗪‑2‑基)吡咯烷‑3‑醇甲磺酸盐原料药质量研究中相关杂质定性和/或定量分析的用途。
    公开号:
    CN110054617A
  • 作为产物:
    描述:
    1-叔丁氧碳基-3-吡咯烷酮盐酸 作用下, 以 乙醚二氯甲烷 为溶剂, 反应 3.0h, 生成 3-吡咯烷酮盐酸盐
    参考文献:
    名称:
    基于N-甲苯磺酰hydr和硼酸涉及腈的烯丙基烷基化反应的杂环反应
    摘要:
    通过N-甲苯磺酰hydr和硼酸之间的多米诺环化反应,合成了具有全碳四元桥头中心的多环分子。通过环过环杂环化反应,一般级联反应的变体已被用于制备3-奎宁环酮和相关的生物碱样支架。此外,使用3-氰基丙基和4-氰基丁基硼酸以及α,β-不饱和N-甲苯磺酰基hydr酮通过史无前例的正式[ n +1]环化反应,包括了Hajos-Parrish酮的立体选择性螺环化反应,形成了螺环。所描述的所有新反应的共同特征是通过形成两个Csp 3来创建全碳四元中心-C键合在肼基碳原子上。基于DFT的计算表明发生了级联过程,其中涉及重氮化合物碳羰基化,然后在中间烯丙基硼酸上进行1,3-硼酸重排,并形成新颖的硼氮杂-氮烯环化反应。
    DOI:
    10.1002/chem.201803309
点击查看最新优质反应信息

文献信息

  • [EN] FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS<br/>[FR] INDOLES FONCTIONNALISÉS ET SUBSTITUÉS UTILISÉS EN TANT QU'AGENTS ANTI-CANCÉREUX
    申请人:NOVOGEN LTD
    公开号:WO2015074123A1
    公开(公告)日:2015-05-28
    The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.
    本发明涉及抗肌球蛋白化合物,其制备方法,以及利用本发明的化合物治疗或预防增殖性疾病,优选癌症的方法。
  • ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
    申请人:NOVARTIS AG
    公开号:US20180271837A1
    公开(公告)日:2018-09-27
    A compound of Formula (I)) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: wherein R 1 through R 3 , and L are as defined herein.
    提供了一种具有治疗听力丧失或平衡紊乱作用的化合物(I)的药物可接受盐,其中R1至R3和L如本文所定义。
  • PYRAZOL DERIVATIVES
    申请人:Aebi Johannes
    公开号:US20090029963A1
    公开(公告)日:2009-01-29
    The invention is concerned with novel pyrazol derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.
    这项发明涉及式(I)的新型吡唑生物, 其中 R 1 ,R 2 ,R 3 ,R 4 ,X和Y如本文所定义,以及其生理上可接受的盐。这些化合物是CCR-2受体和/或CCR-5受体的拮抗剂,可用作药物。
  • [EN] SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS INDAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE RORGAMMAT ET UTILISATIONS ASSOCIÉES
    申请人:MERCK SHARP & DOHME
    公开号:WO2017075182A1
    公开(公告)日:2017-05-04
    The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    本发明涉及式(I)化合物及其药用可接受的盐。此类化合物可用于治疗RORgammaT介导的疾病或状况。
  • 1-BENZYLSPIRO[PIPERIDINE-4,1′-PYRIDO[3,4-b]indole] ‘co-potentiators’ for minimal function CFTR mutants
    作者:Jung-Ho Son、Puay-Wah Phuan、Jie S. Zhu、Soren Lipman、Amy Cheung、Ka Yi Tsui、Dean J. Tantillo、Alan S. Verkman、Peter M. Haggie、Mark J. Kurth
    DOI:10.1016/j.ejmech.2020.112888
    日期:2021.1
    We previously identified a spiro[piperidine-4,1-pyrido[3,4-b]indole] class of co-potentiators that function in synergy with existing CFTR potentiators such as VX-770 or GLGP1837 to restore channel activity of a defined subset of minimal function cystic fibrosis transmembrane conductance regulator (CFTR) mutants. Here, structure-activity studies were conducted to improve their potency over the previously
    我们之前确定了一种螺[哌啶-4,1-吡啶并[3,4-b]吲哚]类共增强剂,它们与现有的 CFTR 增强剂(如 VX-770 或 GLGP1837)协同作用,以恢复定义子集的通道活性最小功能囊性纤维化跨膜电导调节器 (CFTR) 突变体。在这里,进行了结构-活性研究以提高其对先前鉴定的化合物20(最初称为 CP-A01)的效力。37 螺[哌啶-4,1-吡啶并[3,4-b]吲哚]的靶向合成通常使用通用的两步或三步反应方案完成,每一步都具有高效率。构效关系研究确定类似物2i具有 6'-甲氧基吲哚和 2,4,5-三苄基取代基,具有最大的激活 N1303K-CFTR 的效力,EC 50 ∼600 nM 比小分子筛选中鉴定的原始化合物提高了约 17 倍.
查看更多

同类化合物

(5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (2R,2''R)-(-)-2,2''-联吡咯烷 麦角甾-7,22-二烯-3-基亚油酸酯 马来酰亚胺霉素 马来酰亚胺基酰肼盐酸盐 马来酰亚胺基甲基-3-马来酰亚胺基丙酸酯 马来酰亚胺丙酰基-dPEG4-NHS 马来酰亚胺-酰胺-PEG6-琥珀酰亚胺酯 马来酰亚胺-酰胺-PEG6-丙酸 马来酰亚胺-酰胺-PEG24-丙酸 马来酰亚胺-酰胺-PEG12-丙酸 马来酰亚胺-四聚乙二醇-羧酸 马来酰亚胺-四聚乙二醇-丙酸叔丁酯 马来酰亚胺-四聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-六聚乙二醇-羧酸 马来酰亚胺-六聚乙二醇-丙酸叔丁酯 马来酰亚胺-八聚乙二醇-丙酸叔丁酯 马来酰亚胺-二聚乙二醇-丙酸叔丁酯 马来酰亚胺-三(乙烯乙二醇)-丙酸 马来酰亚胺-一聚乙二醇-羧酸 马来酰亚胺-一聚乙二醇-丙烯酸琥珀酰亚胺酯 马来酰亚胺-PEG3-羟基 马来酰亚胺-PEG2-胺三氟醋酸盐 马来酰亚胺-PEG2-琥珀酰亚胺酯 马来酰亚胺 频哪醇硼酸酯 顺式草酸双(-3,8-二氮杂双环[4.2.0]辛烷-8-羧酸叔丁酯) 顺式4-甲基吡咯烷酮-3-醇盐酸盐 顺式4-氟吡咯烷酮-3-醇盐酸盐 顺式3,4-二羟基吡咯烷盐酸盐 顺式3,4-二氨基吡咯烷-1-羧酸叔丁酯 顺式-二甲基 1-苄基吡咯烷-3,4-二羧酸 顺式-N-[2-(2,6-二甲基-1-哌啶基)乙基]-2-氧代-4-苯基-1-吡咯烷乙酰胺 顺式-N-Boc-吡咯烷-3,4-二羧酸 顺式-5-苄基-2-叔丁氧羰基六氢吡咯并[3,4-c]吡咯 顺式-5-甲基-1H-六氢吡咯并[3,4-b]吡咯二盐酸盐 顺式-5-氧代六氢环戊二烯并[c]吡咯-2(1H)-羧酸叔丁酯 顺式-5-乙氧羰基-1H-六氢吡咯并[3,4-B]吡咯盐酸盐 顺式-5-(碘甲基)-4-苯基-2-吡咯烷酮 顺式-5-(碘甲基)-4-甲基-2-吡咯烷酮 顺式-4-氧代-六氢-吡咯并[3,4-C]吡咯-2-甲酸叔丁酯 顺式-3-氟-4-羟基吡咯烷-1-羧酸叔丁酯 顺式-3-氟-4-甲基吡咯烷盐酸盐 顺式-2-甲基六氢吡咯并[3,4-c]吡咯 顺式-2,5-二甲基吡咯烷 顺式-1-苄基-3,4-吡咯烷二甲酸二乙酯 顺式-1-甲基六氢吡咯并[3,4-b]吡咯 顺式-(9CI)-3,4-二乙烯-1-(三氟乙酰基)-吡咯烷 顺-八氢环戊[c]吡咯-5-酮盐酸盐 非星匹宁